Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

In the phase III OPTIMA trial, patients with high-risk anatomical features like node positivity and large tumors did not benefit from adding chemotherapy to endocrine therapy if their genomic score was low. Invasive breast cancer-free survival was identical between chemo and endocrine-only arms for patients with scores under 60.

Related Insights

While ER-positive/HER2-positive breast cancer typically yields lower pCR rates (34% overall), the HER2-DX pCR score revealed an absolute 40% difference between low and high/medium scores. Patients with ER-positive tumors and high or medium scores achieved pCR rates of 58% to 61% with four cycles of THP, effectively identifying candidates who can safely forgo multi-agent chemotherapy despite traditionally lower response expectations.

Real-world data demonstrates that a subset of node-negative (N0) breast cancer patients with high-risk features has a recurrence and mortality rate nearly identical to that of node-positive (N1) patients. This finding justifies intensifying adjuvant therapy with agents like CDK4/6 inhibitors for this seemingly lower-risk group, as was done in the NATALEE trial.

Trials like TaylorX and MINDACT use genomic scores to identify patients with early-stage, HR+/HER2- breast cancer who won't benefit from adjuvant chemotherapy. This avoids significant toxicity for two-thirds to over 80% of patients who would have received it under older guidelines, without compromising their outcomes.

Data from the Optima trial shows the ProSigna (PAM50) gene signature can identify premenopausal ER+ breast cancer patients, even those with high nodal burden, who can safely forgo chemotherapy. For those with a low-risk score, adequate ovarian suppression alone provides sufficient benefit, marking a major step in treatment de-escalation.

For premenopausal patients with extensive nodal disease (e.g., N2), the clinical indication for chemotherapy is so strong that even a low-risk genomic score would not be enough to withhold treatment. This highlights the primacy of clinical staging over genomic data in certain high-risk scenarios.

Contrary to the belief that HR+ breast cancer primarily carries a late recurrence risk, data shows high-risk, node-positive patients can be extremely aggressive early on. With recurrence rates up to 29.1% within five years, this subgroup can perform as poorly, or even worse, than triple-negative breast cancer, highlighting the need for intensive adjuvant therapy.

For patients with 1-3 positive nodes and low-risk biology (e.g., low-grade lobular, low recurrence score), experts are comfortable deferring chemotherapy. This challenges traditional node-based risk assessment, prioritizing tumor biology to avoid unnecessary toxicity in otherwise high-risk patients.

Dr. O'Shaughnessy immediately adopted the Prosigna ROR score from the OPTIMA trial to guide chemotherapy decisions, even in patients with 4-9 positive lymph nodes, trusting tumor biology over high-risk anatomical features.

A registry trial of 3,000 women showed that BCI results caused physicians to change their initial recommendations for or against extended endocrine therapy in 41% of cases. The genomic test also significantly increased patient confidence in their treatment decisions, demonstrating its real-world utility in shared decision-making.

In the CompassHER2 analysis, anatomical factors like nodal involvement and T stage did not predict pathologic complete response, with the lone exception of T3 tumors in ER-negative disease. Dr. Nadine Tung highlights that biological factors—such as receptor expression and genomic signatures—drive chemosensitivity much more than anatomical tumor volume, suggesting clinicians should base de-escalation decisions primarily on biological characteristics.